Medical Isotope Market Report: Trends, Forecast and Competitive Analysis to 2035

Medical Isotope Market

The future of the global medical isotope market looks promising with opportunities in the hospital, diagnostic center, and research institute markets. The global medical isotope market is expected to reach an estimated $11.4 billion by 2035 from $5.8 billion in 2027 with a CAGR of 3.7% from 2027 to 2035. The major drivers for this market are the increasing demand for diagnostic imaging, the rising adoption of targeted therapies, and the growing investment in nuclear medicine advancements.

• Lucintel forecasts that, within the type category, radioisotope is expected to witness higher growth over the forecast period due to appropriately targeted radiation delivery system to treat cancer.
• Within the end use category, hospital is expected to witness the highest growth over the forecast period due to growth in hospital use of nuclear imaging.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to well-established nuclear medicine infrastructure and reimbursement.

Emerging Trends in Medical Isotope Market

Between 2025 and 2027, The Medical Isotope Supply Will Transition To Diversified Productions, Patient-specific Radiopharmaceuticals, and Improved Logistics. Lucintel's Analysis Mirrors The Industry Trends: Rapid increase in demand for oncology services is in conflict with old reactors and reduced supply of isotopes. Therefore, swelling demand requires increased capacity and improved recovery.

• Supply Diversification: In May 2025, The OECD Nuclear Energy Agency reported that over 80% of supply of Mo-99 was still supplied by a few reactors, causing the adoption of accelerator-based production and regional facilities. It is expected that in the next 3 to 5 years the adoption of these products will significantly reduce supply chain disruptions.
• Theragnostic Expansion: Novartis reported that 2024 sales of Pluvicto were about $1.4 billion. Further, in 2025, clinical pipelines began to combine diagnostic radionuclides with therapeutic isotopes. As a consequent, the demand will shift towards integrated isotope platforms with increased value on a per patient basis.
• Domestic Capacity: In 2025, the NNSA program allocated $50 million to strengthen medical isotope capabilities in the US. Similar programs in Europe and Asia will contribute to improved regional supply chains and a reduced reliance on long distance shipments.
• Recycling and Recovery: In 2025, hospitals and isotope processors began to show interest in recovering enriched targets and other reusable resources because of increasing prices and managing waste. Recycling will be adopted because it significantly improves waste resources and limits the potential of outage from reactors.
• Automation and Quality Control: During 2025-2027, automated synthesis, remote handling, and digital batch records will increase among radiopharmaceutical manufacturers. Likewise, production systems are designed to decrease cycle times for short-lived radionuclides to under 30 minutes. Automation will enable facilities to meet more stringent release criteria and increase personalized treatments.

The growth of the medical isotope market relies less on demand compared to other markets and more on reliable production and delivery. Those producers who have access to a reactor and/or an accelerator, and who integrate radiopharmaceutical services and isotope recycling, should dominate the market. Regulators and hospitals will favor those competitors who provide security of supply. Although there are high barriers to entry, the next cycle will favor integrated, comprehensive radiopharmaceutical services platforms over isolated capacity in fragmented markets.

Recent Developments in the Medical Isotope Market

During the 2025-2027 boom period for the medical isotope market, companies will have to spend more on radiopharmaceuticals, reactor upgrades, and improved supply planning. Increasingly, companies are contracting for capacity rather than buying isotopes on the spot market and are focusing on regional supply sufficiency. According to Lucintel, dependable isotope delivery is now of equal importance to cost for isotope buyers, which corroborates statements in recent company filings.

• Positive Regulatory Decision for Earlier-line Radiopharmaceuticals: In March 2025, Novartis received approval to use Pluvicto for eligible prostate cancer patients prior to receiving chemotherapy. This broadens the potential market and will create more pressure on the isotope buying, treatment site construction, and isotope manufacturing in the next 3-5 years.
• Increased Capacity for Commercial Isotope Production: Continued progress in 2025 on SHINE's Wisconsin facility that will have the ability to produce 20,000 curies of molybdenum-99 per week will likely decrease dependence on old reactors and improve the resiliency of supply.
• Partnerships To Produce Lutetium-177: ITM and a European partner engaged in nuclear technologies in February 2025 announced an expansion of their partnership that will allow for the production of no-carrier-added lutetium-177.
• Increased Reactor-based Supply of Medical Isotopes: The Canadian government's proposed funding for the production of medical isotopes combined with the country's new nuclear programs continued in 2025. Diversification of supply away from a few dominant global reactors will improve contracting for hospitals and drug manufacturers.
• Telix Built Its Radiopharmaceutical: Manufacturing in 2025 to support the launch of its products using zirconium-89 and diagnostic isotopes. Localized manufacturing is critical due to the short half-life of nuclear material, which greatly increases the cost of inventory. Suppliers need to locate their manufacturing capacity close to the treatment locations.

The demands are increasingly clinical over commodity. The use of radiopharmaceuticals in prostate cancer is providing more clinical demands, and diagnostic imaging, for the time being, is the higher volume use. Supply capacity announcements doing business will not resolve the market's bottleneck. Regulatory approvals for the manufacturing and transport networks that can address and support the needs for short half-life are required, in addition to hospital teams. The suppliers with a reliable source of inventory, validated capacity, and a strong distribution network will fulfill the long-term opportunities.

Strategic Growth Opportunities in the Medical Isotope Market

The market for medical isotopes is expected to grow from 2024 to 2026 due to a combination of factors, including increased incidence of cancer, maturity of the radiopharmaceutical pipeline, and renewed investment in reactor capacity. Lucintel has identified supply security, targeted therapies, and hospital access as opportunities. Demand is growing due to regulatory approval beyond the imaging market, and isotope producers are focusing on higher-value contracts and reliable distribution of isotopes.

• Theragnostic Radiopharmaceuticals: Diagnostic and therapeutic isotopes, when paired, create higher value treatment pathways. In March 2025, Novartis stated that more than 10,000 patients were treated with Pluvicto since its launch in 2022. This market will grow, as the consumption of isotopes per patient increases due to the expansion of prostate, neuroendocrine, and other tumor indications.
• Molybdenum-99 Supply Diversification: Hospitals need to look for alternatives to aging reactor networks and supply chain disruptions. In January 2025, the OECD Nuclear Energy Agency reported that 13 reactors provide most of the world's supply of Mo-99. New accelerator capacity and low-enriched uranium will improve supply resiliency and support regional buying in the next 3 to 5 years.
• Alpha-emitter Oncology: Actinium-225 and lead-212 are creating a new high-end market for oncology. In June 2025, TerraPower Isotopes stated that they intend to build a U.S. facility that can produce more than 100,000 medical isotope doses annually. Long-term offtake agreements and significant investments in rare alpha emitters will characterize this market.
• Decentralized Isotope Production*: Compact cyclotrons linked to hospitals can significantly decrease reliance on other suppliers. In February 2025, the IAEA published guidelines for radiopharmaceutical production using cyclotrons in over 50 countries. Where short half-lives make transportation economically infeasible, this will increase market access.
• Outsourced Radio Pharmacy Services: Compliance requires hospitals to outsource synthesis, quality assurance, and dose preparation. Recently, the U.S. FDA approved more than 250 radiopharmaceutical products and applications. Automated and contract radio pharmacy models can provide recurring income for higher-throughput patient dosing.

Current demand is not for bulk commodity isotopes, but for reliable, predictable supply for a particular indication. Those producers who have access to a reactor and have developed the infrastructure for handling alpha-emitters, along with regional radio pharmacy networks, will capture a larger profit margin. The best investments will be those that integrate the production of isotopes with clinical evidence and reimbursement planning along with reliable last mile delivery. Hospitals will choose partners who reduce the time to treatment, not simply offer the lowest price.

Medical Isotope Market Drivers and Challenges

improved technology and medical isotope demand is stimulated by increase burden of disease and more investment opportunities. There are isotope demand restraining factors such as short isotope half-lives, expense and safety of production, and constraints in available production capacity. Lucintel predicts the future of the market will be influenced by innovation, investment, and global collaborations.

The factors responsible for driving this market include:

• Innovation in Technology: Nuclear reactors, accelerators, cyclotrons, and isotope separating techniques can be refined in order to increase the availability and the clinical utility of isotopes. Therapy and diagnostics can be integrated into a single medical intervention for personalized therapy. The FDA, in March 2025, reported on the approval of more than sixty radiopharmaceuticals. It reflects the growing clinical importance of therapeutic radionuclides. The next five years will see an improvement in radiopharmaceuticals and waste reduction as well as an increase in the available range of therapies through the combination of radiopharmaceuticals with nuclear medicine.
• Increase in Burden of Disease: The increase burden of cancer and diagnostic imaging will increase demand for isotopes such as technetium-99m, fluorine-18, lutetium-177, and actinium-225. Older populations will also require more cardiovascular, neurological, and oncology exams. The World Health Organization in February 2025 projected that cancer will be a burden to 35 million people by 2050, and this will drive the need for improved diagnostics and therapeutics. The next three to five years will see increased patient numbers and earlier screenings used in emerging healthcare systems, which will increase the demand for isotopes.
• Growth of Targeted Radiotherapy: Firstly, targeted radiotherapy has potential because it delivers radiation directly to cancer cells and minimizes radiation exposure and damage to healthy surrounding cells. As a result, there is an increasing demand for beta and alpha emitting isotopes for use in prostate, neuroendocrine, and other difficult to treat cancers. Precision oncology is a rapidly developing field and in January 2025 the U.S. National Cancer Institute recognized radiopharmaceutical therapy as a rapidly developing precision-oncology field. In the next three to five years, the clinical adoption of radiopharmaceuticals and new approvals will create a demand for medical isotopes and other related infrastructure.
• Government Investment and Infrastructure: Secondly, the supply of medical isotopes will be improved by increased public funding for isotope production, research reactors, and particle accelerators. Nuclear medicine centers will increase production and reduce the impact of isotope shortages. Governments are also investing more to improve the supply of critical isotopes to improve the timeliness of cancer diagnosis and treatment. In May 2025, the International Atomic Energy Agency (IAEA) extended its coordinated nuclear medicine programs to over 170 member states. In the next three to five years, the public funding of these programs will decrease the dependence on a small number of producers, and increase the availability of isotope-based health care.
• Manufacturing Efficiency and Supply Diversification: Better producer use of materials, recycling of enriched material, automation of processing, and establishment of many paths for distribution will result in lower loss of production and higher reliability of the supply even when the half-lives of isotopes produced are very short. In April 2025, international suppliers continued to increase production of molybdenum-99 that is not uranium based, thus diversifying the supply of technetium-99m. Over the next 3 to 5 years the diversity of manufacturing and better logistics will decrease disruption and improve the predictability of delivery and help health-care professionals meet the challenge of increasing, unpredictable demand for isotopes.

The challenges facing this market include:

• Rapid Decay and The Complexity of Distribution: Many medical isotopes have rapid decay, which means that the scheduling of production and delivery, as well as the movement of the isotopes through customs, will be time critical. Even short delays will lead to a decrease in activity and an increase in the cost of the procedure. In June 2025, the International Air Transport Association reported that shipping radioactive medical isotopes had very specialized requirements, meaning that the logistics of these shipments is very complex. In the next 3 to 5 years, the rapid increase in demand will be placing lots of pressure on producers and logistics to create more regional production and shipping with faster and better coordinated inventories.
• High Capital Costs and Limited Infrastructure: Requirements for reactors, cyclotrons, hot cells, shielding systems, quality laboratories, and specialized treatment centers require considerable funding. The lack of trained staff and an insufficient nuclear medicine infrastructure in many lower-income countries pose barriers to patient access, even if isotopes are available. The International Atomic Energy Agency reported in March 2025 that there continues to be a disparity in radiotherapy and nuclear medicine capacity around the world. The next couple years will likely have funding gaps that will result in slower market growth and increase geographic inequality and the slow adoption of new therapeutic isotopes to augment healthcare operations in urban centers.
• Regulatory, Safety, and Supply Issues: There are many requirements for the production, transport, and clinical validation of medical isotopes and the management of waste, which creates a wide variety of impediments for medical isotopes. The approval process is tedious and there are many disruptions that can occur and affect the supply, such as reactor outages, restrictions on enriched materials, geopolitical tensions, and shortages of raw materials. In September 2025, the regulators began intensifying their efforts to monitor radiopharmaceutical manufacturing and radiation safety. In the next 3 - 5 years, companies will be forced to invest more to ensure supply and maintain production, which will likely delay product introductions and create incentives for companies to form stronger partnerships and assured redundant production.

Strong market growth is expected in the long term as cancer cases increase and so do personalize medicine, targeted radiotherapy and diagnostic imaging. There will also be growth in more advanced isotope technologies and greater government investments. Isotope shortages will continue to remain due to short half-lives, high capital costs, and uncertainty in PE supply. Government regulatory barriers will also present significant obstacles to isotope supply. Technological innovation will allow companies to gain a competitive advantage through improved manufacturing systems and logistics in combination with better regulation partnerships. The market will grow to the extent that rapid innovation is balanced with the safe and cost-effective supply of isotopes, meeting the demand of global health infrastructure.

List of Medical Isotope Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies medical isotope market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the medical isotope market companies profiled in this report include-

• Canadian Nuclear Laboratories
• IBA Radiopharma Solutions
• Jubilant Radiopharma
• NorthStar Medical Radioisotopes
• GE Healthcare
• Isotopen Technologien Munchen
• Curium

Medical Isotope Market by Segment

The study includes a forecast for the global medical isotope market by type, application, end use, and region.

Medical Isotope Market by Type [Value ($B) from 2019 to 2035]:

• Stable Isotopes
• Radioisotopes

Medical Isotope Market by Application [Value ($B) from 2019 to 2035]:

• Diagnostic
• Nuclear Therapy

Medical Isotope Market by End Use [Value ($B) from 2019 to 2035]:

• Hospitals
• Diagnostic Centers
• Research Institutes

Medical Isotope Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Medical Isotope Market

The medical isotope market is in a cycle of policy-driven investment as governments fund molybdenum-99, lutetium-177, and actinium-225 supplies. From 2025 to 2027, European and Asian programs are expected to combine reactor, accelerator, and international collaboration components. As per the latest Lucintel report, supply chain localization is a key focus for industry planners.

• United States: For domestic production, the Department of Energy presented a $150 million grant in June 2024 to SHINE Technologies; it will support a commercial molybdenum-99 facility. NRC and FDA work on SHINE's production platform continues. SHINE's production is expected to reduce reliance on import of reactor produced molybdenum-99 over the next three to five years.
• China: The China National Nuclear Corporation (CNNC) and related facilities continued and advanced their radionuclide activities. These include continuing work on lutetium-177 and actinium-225, that is, accelerator based, for 2025. For 2025, it is reported that over 20 medical cyclotrons operated in China.
• Germany: Eckert & Ziegler (E&Z) continued developing their isotope infrastructure in Berlin. In 2025, a reported investment of €30 million will enable E&Z to expand production. ITM continued developing manufacturing in Europe of radioligand therapies.
• India: The Department of Atomic Energy and Bhabha Atomic Research Centre continued advances in commercialized indigenous radioisotopes and BRIT continued advances through the expansion of coverage of therapeutic products; India had over 400 SPECT and PET infrastructure by 2025. This institutional growth is significant because local radioisotope production can support greater treatment availability and can lessen the risk of imports.
• Japan: JAEA and its domestic pharmaceutical partners continued their research on accelerator-based actinium-225; Nihon Medi-Physics expanded its work on radiopharmaceuticals; Japan set production targets for several hundred giga-becquerels for its isotope initiatives in 2025. This is important because Japan needs reliable domestic supply in order to achieve its planned expansion of targeted alpha therapy.

Features of the Global Medical Isotope Market

• Market Size Estimates: medical isotope market size estimation in terms of value ($M).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: medical isotope market size by type, application, end use, and region in terms of value ($M).
• Regional Analysis: medical isotope market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the medical isotope market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the medical isotope market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the medical isotope market by type (stable isotopes and radioisotopes), application (diagnostic and nuclear therapy), end use (hospitals, diagnostic centers, and research institutes), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?